Sonapax, 10 mg 60 pcs

Sonapax is neuroleptic.

Inhibits dopamine and adrenergic transmission at the level of the reticular formation of the trunk (mainly) and the cerebral cortex.

It has antipsychotic (observed after 10-14 days of use) and mild antidepressant effects.

Blocks H1-antihistamine and peripheral m-cholinoreceptors.

It has the most expressed antihistamine and anticholinergic effect among all drugs of the group of neuroleptics.

Indications

Schizophrenia, including paranoid, schizoaffective disorders; psychosis, including involutional; psychosomatic disorders; depressive states accompanied by feelings of fear; withdrawal syndrome in chronic alcoholism, itching (severe, painful) in skin diseases, behavior disorders (increased psychomotor activity) in children.

Active ingredient

Thioridazine

Composition

Active ingredient:

Tioridazine hydrochloride – 10 mg

Ancillary substances:

Corn starch,

Colloidal silicon dioxide (aerosil), <

Lactose,

Gelatin,

stearic acid,

talc,

sucrose,

Arabian gum,

dye – cochineal red

How to take, the dosage

Internal. Dosing regimen is individual.

Adults:

• In acute psychosis, mania, schizophrenia and agitation depressions In outpatients -150-400 mg per day; inpatients 250-800 mg per day. Treatment usually begins with low doses. 25-75 mg daily, gradually increasing to the optimal therapeutic dose, which is usually achieved within 7 days, and the antipsychotic effect is noted after 10-14 days. The course of treatment is several weeks. Maintenance daily dose: 75-200 mg once before bedtime. The drug should be withdrawn gradually.
• In the treatment of the elderly Usually low doses are used: 30-100 mg per day.

In mental and emotional disorders:

• In mild disorders, 30-75 mg per day.
• In moderate disorders, 50-200 mg per day.

Start treatment with low doses, gradually increasing them to the optimal therapeutic dose.

In psychosomatic disorders, 10-75 mg per day.To suppress severe itching, the dose of the drug is set individually and should not exceed 200 mg.

Children:

• From 4 to 7 years – 10-20 mg per day. Frequency of administration – 2-3 times a day.
• From 8 to 14 years – 20-30 mg per day. Frequency of administration – 3 times a day.
• From 15 to 18 years – 30-50 mg per day. Frequency of administration – 3 times a day.

.

Interaction

Synergism with general anesthetics, opiates, barbiturates, ethanol, atropine.

It enhances hepatotoxic effect of antidiabetic drugs.

With amphetamine – acts antagonistically. With levodopa – reduces the antiparkinsonian effect.

The use with adrenaline – may lead to a sudden and pronounced decrease in BP.

With guanethidine reduces the antihypertensive effect of the latter, but increases the effect of other antihypertensive agents, which increases the risk of significant orthostatic hypotension.

Decreases the effect of anti-coagulants. The effect of Sonapax may be weakened by anticonvulsants, cimetidine.

Hinidine potentiates the cardiodepressant effect.

Ephedrine – promotes paradoxical BP reduction. Sympathomimetics – increases arrhythmogenic effects.

Probucol, astemizole, cisapride, disopyramide, erythromycin, pimozide, procainamide and quinidine contribute to additional prolongation of the QT interval, which increases the risk of ventricular tachycardia.

The antithyroid drugs increase the risk of agranulocytosis.

Limits the effect of appetite reducers (except for fenfluramine).

Decreases the effectiveness of the vomiting action of apomorphine, increases its CNS depressant effect.

Enhances the plasma concentration of prolactin and interferes with the action of bromocriptine.

When used together with tricyclic antidepressants, maprotiline, MAO inhibitors, antihistamines, prolongation and enhancement of sedative and anticholinergic effects are possible.

With thiazide diuretics – increase of hyponatremia.

With lithium preparations – decreased gastrointestinal absorption, increased rate of renal excretion of lithium ions, increased severity of extrapyramidal disorders, the early signs of lithium intoxication (nausea and vomiting) may be masked by the antiemetic effect of perphenazine.

When combined with beta-adrenoblockers contributes to an increased hypotensive effect, there is an increased risk of irreversible retinopathy, arrhythmias and tardive dyskinesia.

.

Special Instructions

The morphological composition of the blood should be monitored during treatment: refrain from drinking ethanol and engaging in potentially hazardous activities requiring increased concentration and rapid psychomotor reactions.

Impact on the ability to drive vehicles and operate machinery in motion: Sonapax impairs motor coordination and reduces reaction, especially at the beginning of treatment, so during treatment with the drug the patient should refrain from driving vehicles and operating moving machinery.

.

Contraindications

Hypersensitivity (including to phenothiazine derivatives), depression (acute condition), coma, pheochromocytoma, porphyria, hematopoietic insufficiency, first trimester and last week of pregnancy, children under 4 years.

.

Side effects

Nervous system and sensory organs: parkinsonism syndrome, dyskinesia, akathisia, somnolence, apathy, irritability, depression, delirium, seizures, thermoregulation disorders.

Cardiovascular system and blood (hematopoiesis, hemostasis): tachycardia, orthostatic hypotension, agranulocytosis, leukopenia, eosinophilia, pancytopenia, thrombocytopenic purpura.

Gastrointestinal tract disorders: constipation, cholestatic jaundice.

Skin disorders: allergic reactions, discoid lupus erythematosus, photosensitization.

Other: hyper- or hypoglycemia, gynecomastia, menstrual cycle disorders, decreased libido.

.

Overdose

Symptoms: somnolence, confusion, urinary retention, disorientation, coma, areflexia, hyperreflexia, dry mouth, stuffy nose, postural hypotension, respiratory center depression, seizures, hypothermia.

The treatment is symptomatic, aimed at reducing absorption and accelerating excretion of the drug. Gastric lavage with activated charcoal solution, laxatives (e.g., magnesium sulfate ). Injection of isotonic solutions. Monitor cardiovascular and respiratory function. If necessary, sequentially carry out artificial lung ventilation, monitor the function of the cardiovascular system, prevent the development of metabolic acidosis. There is no specific antidote.

.